Lebrikizumab Demonstrates Consistent Efficacy at 16 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis Regardless of Baseline Disease Severity - Gold LS; Eyerich K; Sofen H; Herranz P; Kircik L; Bewley T; Wolf E; Gallo G; Ding Y; Yang FE; Pau-Charles I; Gooderham M (SKIN: Journal of Cutaneous Medicine, 2023)